Reproductive Late Effects in Female Survivors of Childhood Cancer by Gnaneswaran, Shivany et al.
Hindawi Publishing Corporation
Obstetrics and Gynecology International
Volume 2012, Article ID 564794, 7 pages
doi:10.1155/2012/564794
Review Article
Reproductive Late Effectsin Female Survivors of
ChildhoodCancer
ShivanyGnaneswaran,1 Rebecca Deans,1,2,3 and RichardJ. Cohn1,3
1University of New South Wales, Sydney, NSW 2052, Australia
2Royal Hospital for Women, Barker Street, Randwick, NSW 2031, Australia
3Centre for Children’s Cancer and Blood Disorders, Sydney Children’s Hospital, High Street, Randwick, NSW 2031, Australia
Correspondence should be addressed to Richard J. Cohn, richard.cohn@sesiahs.health.nsw.gov.au
Received 26 October 2011; Revised 27 December 2011; Accepted 25 January 2012
Academic Editor: Catherine Poirot
Copyright © 2012 Shivany Gnaneswaran et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Childhood cancer treatments can cause female reproductive late eﬀects. Radiation to the hypothalamic-pituitary-ovarian axis
is associated with altered menarche, miscarriage, and implantation failure. Patients who receive chemotherapy and/or ovarian
radiation are at risk of premature ovarian failure; the risk increases with increasing radiation dose, alkylating agent score,
combination therapy, and older age at treatment. Ovarian reserve may be assessed using antimullerian hormone assay and
ultrasound measurements of ovarian volume and antral follicle count; however, their eﬃcacy is poorly established in this cohort.
Fertility preservation options including cryopreservation, oophoropexy, and gonadotropin-releasing hormone analogues may be
initiated prior to treatment, although most are still considered experimental. Uterine radiation has been linked to pregnancy
complications including miscarriage, premature delivery, stillbirth, low-birth-weight and small-for-gestational-age infants. This
paper summarises the literature on female reproductive late eﬀects. The information should facilitate counseling and management
of female survivors throughout their reproductive lives.
1.Introduction
Cancer is the second commonest cause of death in children
in developed countries [1]. Common childhood cancers
includeleukaemia,lymphoma,rhabdomyosarcoma,neurob-
lastoma, Wilms’ tumour, central nervous system tumours,
and germ cell tumours [2, 3]. Most of these cancers are
curable using chemotherapy, radiotherapy, or surgery, either
aloneorincombination[2,4].Moreaggressiveortreatment-
refractory cancers require intensive multimodal therapies
involving multiagent chemotherapy [4].
As a result of advances in paediatric cancer treat-
ment protocols, survival rates from childhood cancers have
improved dramatically over the past 3 decades [2]. The
expected 5-year survival rate for newly diagnosed patients is
at least 70% [2, 5].
Despite being highly successful in treating cancers,
therapies such as chemotherapy and radiotherapy have also
p r o d u c e dc o m p l i c a t i o n sr e f e r r e dt oa sl a t ee ﬀects [6]. Late
eﬀects can either arise during treatment or shortly thereafter
topersistaschronicconditions.Theymayalsomanifestyears
after the completion of therapy [4]. Late eﬀects encompass a
rangeofclinicalconditionsincludingneurocognitivedeﬁcits,
skeletal deformities, cardiopulmonary, and renal and hepatic
damage, as well as endocrine and reproductive dysfunction.
It is estimated that 60–75% of survivors of childhood cancer
will develop at least one late eﬀect as a direct result of their
treatment [7].
T h ef e m a l er e p r o d u c t i v es y s t e mi se s p e c i a l l yv u l n e r a b l e
to late eﬀects of cancer therapy. Normal hypothalamic,
pituitary, ovarian, and uterine functions as well as ade-
quate ovarian reserve are required for pubertal progression,
fertility and pregnancy [2]. Potential late eﬀects on the
female reproductive system can therefore occur as a result
of chemotherapy and/or radiation to the hypothalamic-
pituitary-ovarian (HPO) axis, ovaries or uterus [2, 4].
Although the late eﬀects show individual variation, there is
a strong relationship with the treatment received [2].2 Obstetrics and Gynecology International
The purpose of this paper is to summarise the liter-
ature regarding the inﬂuence of childhood cancer ther-
apies on female reproductive late eﬀects, measures to as-
sess ovarian reserve, and options for fertility preservation.
Literature was obtained from electronic resources includ-
ing Medline, Embase, PubMed Central, Journals@Ovid, and
The Cochrane Library (including The Cochrane Database
Of Systematic Reviews). The Medical Subject Headings
(MeSH) and keywords “childhood cancer,” “pediatrics/child/
paediatric,” “neoplasms/malignancy,” “menarche,” “meno-
pause/premature menopause/amenorrhea/female infertility/
ovarian failure,” “pregnancy/pregnancy complications/preg-
nancy outcome,” “fertility preservation,” “GnRH ana-
logues/GnRH agonist,’ “ovarian tissue cryopreservation,”
“embryo freezing/em-bryo cryopreservation,” and “oocyte
cryopreservation” were used. Relevant references cited by the
obtained literature were also acquired independently.
2. Late Effects of Radiotherapy to the
Hypothalamic-Pituitary-OvarianAxis
Children who receive radiation to the brain are at risk of
damage to the hypothalamus and pituitary with subsequent
changesinthereleaseofpituitarygonadotropinstostimulate
the ovaries [8].
Earlier timing of menarche has an association with
cranial radiation. Low dose radiation (18–24Gy), as part
of treatment for acute lymphoblastic leukaemia (ALL), and
early menarche has been reported in previous studies [9–14].
Currently, although many ALL treatment protocols favour
more intensive alkylating agent chemotherapy, 10–15% of
patients continue to receive cranial radiation upfront [15].
Within this cohort there remains a link with early menarche;
however, there is no increased risk amongst patients treated
for ALL with chemotherapy only [15]. Patients treated with
higher doses of radiation for CNS tumours are also at risk
of an earlier menarche, with one study of 235 survivors
exposed to cranial radiation prior to menarche determining
doses >50Gy to be a signiﬁcant independent risk factor [16].
Furthermore, a younger age at cranial radiation has been
independently associated with early menarche in patients
treated for ALL and CNS tumours (<5y e a r sa n d<4y e a r s ,
resp.) [15, 16].
Patients who receive radiation to the lumbar-sacral spine
have an increased risk of delayed menarche [11–13, 15]. This
is presumably due to indirect radiation eﬀects on the ovaries.
However, as some of these patients also receive radiation
to the brain, it is possible that gonadotropin deﬁciency
may contribute to their delayed menarche. Radiation doses
>50Gy to the hypothalamus/pituitary in combination with
spinal radiation have been reported to increase the risk of
delayed menarche 12-fold compared to patients who do not
receive radiation [16]. Although alkylating agent exposure
is known to increase the risk of gonadal damage, no such
associations have been noted to date.
Lower pregnancy rates have been described in patients
who received cranial radiation, although the radiation doses
reported to decrease the risk of a pregnancy are variable.
In one study of 5149 female survivors [17] radiation doses
>30Gy to the hypothalamus/pituitary were a signiﬁcant risk
factor for not having a pregnancy, whilst in another study
[18] a decreased risk of pregnancy was noted in patients
receiving >22Gy to the hypothalamus/pituitary. Lower dose
exposures (18–24Gy) used in the treatment of ALL have also
been shown to decrease fertility rates in female survivors
compared to sibling controls [19, 20], particularly in patients
whoreceive18–24Gytothebrainwithintwoyearsofmenar-
che and whose age at ﬁrst pregnancy is 18–21 years [19].
Further studies of proven fertility are limited to clarify these
ﬁndings; however, Bath et al. [21] have observed decreased
luteinizing hormone (LH) excretion, decreased LH surge,
and high frequency of short (≤11 days) luteal phase (despite
regular (26–30 day) ovulatory menstrual cycles) in 12 ALL
survivors treated with 18–24Gy cranial irradiation. These
ﬁndings could suggest subnormal mid-cycle LH surge and
decreased progesterone production by the corpus luteum as
one of the causal factors for delayed endometrial maturation
and subsequent implantation failure and/or infertility [18].
It has been suggested that cranial radiation increases the
riskofmiscarriage(<24weeks)possiblythroughimpairment
of HPO axis function [22]. Two studies have shown some
support for this hypothesis reporting 1.8- and 1.4-fold
signiﬁcantly increased risks, respectively, amongst survivors
treated with cranial radiation only [23, 24]. Another study
reported an increased risk amongst patients treated with
cranial and craniospinal radiation; however, there was no
distinction in the risk of ﬁrst-trimester miscarriage (<12
weeks) between these treatment groups [25].
3 .Lat eEf f ec t so fT r eatm e n tt ot h eOvarie s
There is a relationship between age and the number of
primordial follicles in human ovaries [2]. At 5-6 months
gestation, the number of follicles reaches a maximum of
approximately 7 × 106. Thereafter, there is an exponential
decline with approximately 400 follicles released as mature
oocytes during the reproductive lifespan. Accelerated decline
in follicle number occurs after 35 years until menopause
occurs. This occurs at an average age of 50.4 years in the
Western world [2, 26–30].
Any radiation or chemotherapy will deplete the number
of follicles and induce damage to the ovaries [2]. Patients
who are older at the time of either treatment have an
increased risk of ovarian damage as there is a greater reserve
of primordial follicles in younger patients [2, 25, 28]. It has
also been suggested that the oocytes present in older patients
are more vulnerable to gonadal toxins [31, 32]. Accordingly
the mean sterilising dose of radiation to the ovary at 12 years
of age has been estimated at 18Gy compared to 9.5Gy at 45
years of age [33].
4. DirectRadiotherapy to the Ovaries
Additional to scatter from lumbar-sacral radiation, the
ovaries can also be irradiated directly as part of abdom-
inal, pelvic, or total body irradiation. Premature ovarian
failure may take the form of either acute ovarian failure
(AOF), where there is a loss of ovarian function during orObstetrics and Gynecology International 3
shortly after the completion of cancer therapy, or premature
menopause, deﬁned as menopause younger than 40 years in
survivors who retain ovarian function following treatment
[28, 33]. The speciﬁc risk of premature ovarian failure after
direct radiation to the ovaries is site and dose-dependent
[28, 34]. Stillman et al. [35]r e p o r t e do v a r i a nf a i l u r ei nn o n e
of 34 survivors who had both ovaries outside of the ﬁeld of
abdominal radiation, in 14% of 35 survivors whose ovaries
were at the edge of the radiation ﬁeld, and in 68% of 25
survivors who had both ovaries entirely within the ﬁeld
of irradiation. Previous studies have demonstrated ovarian
doses >10Gy to be linked to a high risk of AOF, especially
doses >20Gy which are associated with the highest rate, with
over 70% of a study cohort of 3390 survivors developing
AOF [34]. Recently, doses as low as 5Gy to the ovaries have
been identiﬁed as a signiﬁcant risk factor for not having a
pregnancy, presumably due to ovarian failure [17]. The LD50
(the radiation dose required to kill 50% of oocytes) of the
human oocyte has been estimated at <2Gy[25, 28].
5. Chemotherapy
Factors aﬀecting the risk of ovarian injury in children
treated with chemotherapy include the speciﬁc agent, the
number of agents, and the cumulative dose [4]. Several
chemotherapeutic agents when given at high doses are
recognised as toxic to young ovaries including alkylating
agents, cisplatin procarbazine, and the nitrosoureas (CCNU
and BCNU) [2, 36]. There is currently no data on threshold
dosestocauseovarianfailure,althoughithasbeennotedthat
exposures to procarbazine at any age or cyclophosphamide
between 13 and 20 years are independent risk factors for
AOF [34]. Additionally, cyclophosphamide and CCNU have
been associated with a lower risk of pregnancy, with fertility
rates decreasing with increasing doses of these agents [17].
Increasing alkylating agent score (based on the number
of alkylating agents and cumulative doses) has also been
identiﬁed as a risk factor for both nonsurgical premature
menopause [34] and decreased fertility, with one study of
5149 survivors demonstrating that alkylating agent scores of
three and four were associated with a lower observed risk of
pregnancycomparedtopatients whohadnoalkylating agent
exposure [17].
6. Combination Radiotherapy and
Chemotherapy
A combination of radiation to the ovaries and chemotherapy
poses the greatest risk of ovarian failure [25, 28, 37–39].
Amongst patients who are treated with alkylating agents
plus abdominopelvic irradiation, 30–40% are estimated to
develop non-surgical premature menopause [37, 39].
7. Assessment of OvarianReserve
7.1. Hormonal Markers. A slow and steady compensatory
rise in early follicular phase follicle-stimulating hormone
(FSH) has traditionally been used as marker of peri-
menopause and ovarian reserve [28, 40]. Unless signiﬁcantly
elevated however, early follicular phase FSH as an isolated
test is not a sensitive early marker of diminished ovarian
reserve [28]. Some women may experience transiently
elevated FSH unrelated to their pool of follicles, which
can add to potential erroneous presumptions of premature
menopause. Inhibin-B is another hormonal marker which
has been proposed to assess ovarian reserve. It is produced
by follicles following recruitment during the early follicular
phase and has been shown to decrease with age and during
premature ovarian failure [40, 41]. However, it is a fairly late
marker of reduced follicle reserve as levels do not decrease
gradually with age [40].
Levels of antimullerian hormone (AMH) are more
reﬂective of the number of preantral follicles and are thus a
markerofoocytepool[28,40,42,43].AMHlevelsinwomen
of reproductive age appear to have a greater sensitivity and
speciﬁcity for ovarian reserve over FSH and inhibin-B [40,
44]. Levels are independent of the phase of the ovarian cycle
andshouldnotvarysigniﬁcantlybetweenmenstrualcyclesas
levels are not dependent on the feedback mechanisms of the
HPO axis [28, 40, 42–44]. Importantly, AMH levels decrease
steadily over time and often fall before other markers of
ovarian ageing occur [42] .T h e r ei sad e m o n s t r a t e da g e -
dependent decrease after 30 years, with a decline in AMH
levels below 0.086µg/L signalling menopause [45]. Although
a promising marker for ovarian reserve, its eﬃcacy in
assessing premature menopause and chance of pregnancy in
young patients after cancer treatment is not well established,
and more data are required.
7.2. Ultrasonographic Markers. Transvaginal ultrasound as-
sessments of total ovarian volume and antral follicle count
(AFC) are noninvasive and accurate tests of ovarian reserve
as both exhibit an age-related decline [28, 40]. Mean pre-
menopausal ovarian volumes of 4.9cm3 compared to mean
postmenopausal volumes of 2.2cm3 have been determined
[46]. The mean AFC is 15 at 25–34 years of age and decreases
to 4 at 41–46 years of age [47]. AFC has also been shown to
correlate tightly with plasma levels of AMH [48].
8. Options for Fertility Preservation
There are two main approaches to preserving fertility in
female childhood cancer survivors, namely, cryopreservation
of ovarian tissue, oocytes, and embryos, and interventions to
minimise the eﬀects of cancer therapies on the ovaries [49].
Within these approaches, there are established practices and
experimental strategies.
8.1. Cryopreservation. Embryo cryopreservation is the main
established method of fertility preservation, with delivery
rates per embryo transfer ranging between 10–40% depend-
ing upon the age of the female partner and quality of oocyte
[49, 50]. However, this option is of limited value in children
as the patient must be postpubertal and have a partner or
use donor sperm. This process also requires at least one4 Obstetrics and Gynecology International
cycle of ovarian stimulation which may not be possible
when chemotherapy needs to be commenced immediately
or where stimulation is contraindicated due to hormone-
sensitive tumours [49, 51, 52].
In contrast, oocyte cryopreservation may be utilised in
s o m ea d o l e s c e n tg i r l sa si td o e sn o tr e q u i r ep a r t n e ro r
donor sperm. However, the method also requires the use
of ovarian stimulation [53] and its success is dependent
on the total number of oocytes retrieved (<10 oocytes is
associatedwithminimalchanceofpregnancy),whichisoften
diﬃcult in sexually immature patients [54, 55]. Ongoing
advances in oocyte cryopreservation technique and the use
of intracytoplasmic sperm injection (ICSI) appear to have
improved success rates [53, 54]. In a prospective randomised
controlled trial (RCT) conducted by Smith et al. [56],
oocytesurvival,fertilization,andestablishmentofpregnancy
were signiﬁcantly higher following vitriﬁcation/warming
compared with freezing/thawing. In another RCT [57]f e rt i l -
isationandembryodevelopmentratesusingvitriﬁedoocytes
followed by ICSI approached that of fresh oocytes after
ICSI. Cryopreservation of oocytes has also been described
in association with ovarian tissue cryopreservation (OTC) in
prepubertalgirls,wherebyanyantralfolliclesobservedonthe
ovarian surface at the time of biopsy are aspirated, matured
in vitro and cryopreserved [55, 58]. Accordingly, Revel et al.
[58] were able to cryopreserve 11 mature oocytes from three
prepubertal girls aged 5, 8, and 10 years.
Ovarian tissue cryopreservation is the only means of
preserving fertility in prepubertal girls [49, 51, 53, 59]a n d
may also be utilised in girls who do not have enough
time to undergo ovarian stimulation for oocyte and embryo
cryopreservation [49, 51, 53, 57]. Ovarian cortical tissue
is harvested laparoscopically without preparation, cryopre-
served using standard slow-programmed freezing, and is
reimplanted into the pelvic cavity (orthoptic site) or a
heterotopic site once the patient is in remission [51]. The
option has greater fertility potential in prepubertal girls due
to a greater density of primordial follicles in the harvested
tissue [54, 55]. This process has the added advantage of
endogenous hormone production by the ovarian tissue, and
avoidance of hormone therapy for bone health maintenance.
To date, ten live births have been reported following orthop-
ticreimplantation offrozen-thawedovariancortexharvested
from postpubertal girls [55], although the origins of these
pregnancies are not deﬁnite as a vast majority of patients
have demonstrated restoration of follicular growth and
ovulation [55]. Risks of OTC include the surgical risks asso-
ciated with the invasive procedure. An additional concern
is reimplantation of the primary tumour and/or malignant
transformation of reimplanted tissue, which is possible with
leukaemias, neuroblastoma, and Burkitt’s lymphoma which
arecommonduringchildhoodandmetastasisetotheovaries
[49, 53], although histological analysis of the cryopreserved
ovarian cortex and further methods for monitoring minimal
residual disease have been developed over recent years [55].
8.2. Interventions to Minimise Damage Caused by Cancer
Therapies. Transposition of the ovaries (oophoropexy) out-
side of the ﬁeld of radiation may be performed to reduce
the ovarian radiation dose to 5–10% of that if the ovaries
remained in situ [60]. The ovaries can either be relocated
outside of the pelvis, in the case of pelvic irradiation,
or, in the case of craniospinal irradiation, ﬁxed laterally
as far as possible from the spine [55]. Preserved ovarian
function following oophoropexy outside of the pelvis has
been reported between 16–90% [49, 54]; the wide variability
is due to the inability to calculate and prevent scatter,
combination chemotherapy and diﬀerent radiation doses
[49, 54]. A disadvantage of this technique is the invasive
procedure which needs to occur at a time when the patient
is planning cancer treatment. Moreover, ovarian failure may
ensue if the ovaries are not transposed far enough or if
they revert back to their original position or if the vascular
supply of the ovary is aﬀected by the surgical procedure [49].
Additional issues to consider prior to performing extrapelvic
oophoropexy include problems achieving a spontaneous
pregnancy and diﬃculties with oocyte retrieval for in vitro
fertilisation (IVF) unless a second procedure is performed to
relocate the ovaries back to the pelvis [49, 53]; this problem
is often avoided in the case of lateral oophoropexy for cranial
irradiation as the anatomic relations of the ovary with the
uterus and fallopian tubes are maintained [55]. Commonly,
ovarian biopsy and transposition is performed simultane-
ously for patients undergoing combination therapies.
GnRH (gonadotropin-releasing hormone) analogues
have been suggested as chemoprotective agents. The exact
mechanism remains unclear, although it is hypothesised
that suppression of pituitary gonadotropin production with
subsequent reductions in ovarian follicular cell division and
growth render the follicles less vulnerable to cytotoxic agents
[49]. Their use is limited in prepubertal girls who are
hypogonadal. To date, the evidence for the use of GnRH
analogues is controversial. There are several case series
and small cohort studies that claim beneﬁt [61–63], and a
meta-analysis has shown beneﬁt in this technique; however,
when only high quality studies are included, the results
are not signiﬁcant [64] .Ar e c e n tr a n d o m i s e ds t u d yo f4 9
breast cancer patients with 30-month followup additionally
found no diﬀerence in the incidence of ovarian failure
[65]; however, a prospective multicentre study is currently
underway with anticipated results.
9. Late Effects of Radiotherapy to the Uterus
Radiation to the uterus can impair uterine function, causing
reduceduterinevolume,decreasedmyometrialelasticity,and
some uterine vascular damage [4, 25, 66–68]. Although
data on threshold doses for uterine dysfunction is limited,
earlier studies have reported reduced uterine length, poor
endometrial thickness in response to oestradiol therapy, and
absence of uterine artery blood ﬂow detectable by Doppler
ultrasound in patients treated with 14–30Gy of radiation
to the uterus [67, 69, 70]. The risk of uterine dysfunction
increases with higher radiation doses and ﬁelds involving
a greater uterine volume [4]. Radiation prior to puberty
has also been associated with irreversible damage to the
uterus, with prepubertal uterine morphology observed in
postpubertal patients [68].Obstetrics and Gynecology International 5
Reduced adult uterine volume and blood supply may
restrict foetal growth and the ability to carry the foetus
to term [22]. There is an increased risk of delivering low
birth weight infants (<2.5kg) amongst patients treated with
abdominal/pelvic radiation [22, 23, 25, 71–73]. Patients
who receive >5Gy radiation to the uterus are also sig-
niﬁcantly more likely to deliver small for gestational age
oﬀspring (<10th percentile for gestational age) [25]. Higher
frequencies of preterm birth (<37 weeks) following abdomi-
nal/pelvic radiation have additionally been reported [25, 71,
72, 74] with a more recent study observing a 2-fold elevated
risk of preterm delivery in their cohort of 351 survivors who
received abdominal radiation [22]. There is also an increased
risk of miscarriage [22–24], with Reulen et al. reporting the
risk to be particularly elevated during the second trimester
[22].
In one study of 39 patients who received radiation to
the pelvis a signiﬁcantly increased risk of stillbirth at doses
>10Gy was observed [75]. Additionally, doses as low as 1.0–
2.49Gy were observed to signiﬁcantly increase the risk in
girls treated before menarche [75].Althoughtheexactmech-
anism ofdecreaseduterinevolume andblood supplyonstill-
birthisunknown,itispossiblethattheseeﬀectsmayincrease
the risk of placental or umbilical cord anomalies [75].
10. Conclusion
Although there is individual susceptibility, the late eﬀects
of childhood cancer therapies on the reproductive system
can be anticipated amongst female childhood cancer sur-
vivors throughout their reproductive lives. Girls treated with
radiation to the HPO axis are at risk of abnormal timing
of menarche and pregnancy sequelae including miscarriage
andimplantation failurecontributing to infertility. Survivors
treated with chemotherapy and/or radiotherapy aﬀecting
ovarian reserve are also at risk of premature ovarian failure.
Women with uterine dysfunction following radiotherapy are
at risk of pregnancy complications including miscarriage,
low-birth-weight and small-for-gestational-age infants, pre-
mature delivery, and stillbirth.
These ﬁndings have important implications on coun-
seling and management. Girls and their families should be
counseled regarding options for fertility preservation, the
possibility of abnormal pubertal progression and menstrual
dysfunction. Women who are at risk of premature ovarian
failure should be advised to not delay their childbearing,
have assessment of ovarian reserve with referral for specialist
fertility consultation as required. Pregnant survivors who
have had radiation to the uterus should be managed in a
high-risk obstetric unit.
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